{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:41:27Z","timestamp":1789072887580,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,16]]},"DOI":"10.7759\/cureus.97002","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T04:30:49Z","timestamp":1763353849000},"source":"Crossref","is-referenced-by-count":1,"title":["Immune Checkpoint Dysregulation in Autoimmune Disorders: A Narrative Review of Therapeutic Implications"],"prefix":"10.7759","author":[{"given":"Diwan Mahmood","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahavadi","family":"Sriharsha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihita","family":"Mahavadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaw","family":"Kishore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-025-01180-1","article-title":"T cell dysregulation in rheumatoid arthritis: from genetic susceptibility to established disease","volume":"27","author":"Chin A","year":"2025","unstructured":"Chin A, Small A, Wong SW, Wechalekar MD. T cell dysregulation in rheumatoid arthritis: from genetic susceptibility to established disease. Curr Rheumatol Rep. 2025, 27:14. 10.1007\/s11926-025-01180-1","journal-title":"Curr Rheumatol Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1616231","article-title":"Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions","volume":"16","author":"Chen Y","year":"2025","unstructured":"Chen Y, Li X, Zhang J, et al.. Global clinical trials on stem cell therapy for autoimmune diseases: trends and future directions. Front Immunol. 2025, 16:1616231. 10.3389\/fimmu.2025.1616231","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.22034\/iji.2025.103848.2859","article-title":"Interaction between Tfh\/TFR ratio and regulatory B cell in autoimmune diseases","volume":"22","author":"Zhu C","year":"2025","unstructured":"Zhu C, Ni X, Xu J, Wang H, Shen H. Interaction between Tfh\/TFR ratio and regulatory B cell in autoimmune diseases. Iran J Immunol. 2025, 22:1-12. 10.22034\/iji.2025.103848.2859","journal-title":"Iran J Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582125","article-title":"Editorial: the role of negative immune checkpoints in the treatment of systemic lupus erythematosus and rheumatoid arthritis","volume":"16","author":"Li J","year":"2025","unstructured":"Li J, Liu J, Dai L, Wang X, Shi Y. Editorial: the role of negative immune checkpoints in the treatment of systemic lupus erythematosus and rheumatoid arthritis. Front Immunol. 2025, 16:1582125. 10.3389\/fimmu.2025.1582125","journal-title":"Front Immunol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073021","article-title":"Function of immune checkpoints in IgG4-related disease with lacrimal gland involvement: clinical features, serum IgG4 level, immunohistochemical landscape, and treatment responses","volume":"26","author":"Bae DH","year":"2025","unstructured":"Bae DH, Kim YR, Yang W, Kim GI, Lew H, Yoo J. Function of immune checkpoints in IgG4-related disease with lacrimal gland involvement: clinical features, serum IgG4 level, immunohistochemical landscape, and treatment responses. Int J Mol Sci. 2025, 26:3021. 10.3390\/ijms26073021","journal-title":"Int J Mol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17959","article-title":"Regulatory T cell dysregulation in vitiligo: a meta-analysis and systematic review of immune mechanisms and therapeutic perspectives","volume":"64","author":"Lerner G","year":"2025","unstructured":"Lerner G, Nikolaou M, Stoffel C, et al.. Regulatory T cell dysregulation in vitiligo: a meta-analysis and systematic review of immune mechanisms and therapeutic perspectives. Int J Dermatol. 2025, 64:2247-6. 10.1111\/ijd.17959","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-00994-x","article-title":"The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases","volume":"24","author":"Sumida TS","year":"2024","unstructured":"Sumida TS, Cheru NT, Hafler DA. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nat Rev Immunol. 2024, 24:503-17. 10.1038\/s41577-024-00994-x","journal-title":"Nat Rev Immunol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03009-3","article-title":"CD40 ligand antagonist dazodalibep in Sj\u00f6gren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial","volume":"30","author":"St Clair EW","year":"2024","unstructured":"St Clair EW, Baer AN, Ng WF, et al.. CD40 ligand antagonist dazodalibep in Sj\u00f6gren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024, 30:1583-92. 10.1038\/s41591-024-03009-3","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-025-09037-2","article-title":"The role of lactate and lactylation in the dysregulation of immune responses in psoriasis","volume":"68","author":"Wu X","year":"2025","unstructured":"Wu X, Liu C, Zhang C, et al.. The role of lactate and lactylation in the dysregulation of immune responses in psoriasis. Clin Rev Allergy Immunol. 2025, 68:28. 10.1007\/s12016-025-09037-2","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70349","article-title":"Ferroptosis in cancer and inflammatory diseases: mechanisms and therapeutic implications","volume":"6","author":"Shen G","year":"2025","unstructured":"Shen G, Liu J, Wang Y, Deng Z, Deng F. Ferroptosis in cancer and inflammatory diseases: mechanisms and therapeutic implications. MedComm (2020). 2025, 6:e70349. 10.1002\/mco2.70349","journal-title":"MedComm (2020)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1536020","article-title":"Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases","volume":"16","author":"Lu Y","year":"2025","unstructured":"Lu Y, Wang Y, Ruan T, et al.. Immunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases. Front Immunol. 2025, 16:1536020. 10.3389\/fimmu.2025.1536020","journal-title":"Front Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26157101","article-title":"Understanding sex differences in autoimmune diseases: immunologic mechanisms","volume":"26","author":"Kim YR","year":"2025","unstructured":"Kim YR, Jung Y, Kang I, Yeo EJ. Understanding sex differences in autoimmune diseases: immunologic mechanisms. Int J Mol Sci. 2025, 26:7101. 10.3390\/ijms26157101","journal-title":"Int J Mol Sci"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S506221","article-title":"Exosomes in systemic autoimmune diseases: recent advances in diagnostic biomarkers and therapeutic applications","volume":"20","author":"Lv X","year":"2025","unstructured":"Lv X, Liu W, Zhou X, et al.. Exosomes in systemic autoimmune diseases: recent advances in diagnostic biomarkers and therapeutic applications. Int J Nanomedicine. 2025, 20:5137-60. 10.2147\/IJN.S506221","journal-title":"Int J Nanomedicine"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.stress.2025.100785","article-title":"Trichoderma combined with 1-aminocyclopropane-1-carboxylic acid (ACC) soil amendments modulates the root microbiome and improves wheat growth under salinity stress","volume":"15","author":"Zhao H","year":"2025","unstructured":"Zhao H, Zhang L, Liu M, Wang X, Oljira AM. Trichoderma combined with 1-aminocyclopropane-1-carboxylic acid (ACC) soil amendments modulates the root microbiome and improves wheat growth under salinity stress. Plant Stress. 2025, 15:100785. 10.1016\/j.stress.2025.100785","journal-title":"Plant Stress"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011427","article-title":"Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications","volume":"13","author":"Harel M","year":"2025","unstructured":"Harel M, Dahan N, Lahav C, et al.. Decoding resistance to immune checkpoint inhibitors in non-small cell lung cancer: a comprehensive analysis of plasma proteomics and therapeutic implications. J Immunother Cancer. 2025, 13:011427. 10.1136\/jitc-2024-011427","journal-title":"J Immunother Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01068-8","article-title":"Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors","volume":"120","author":"Gergely TG","year":"2025","unstructured":"Gergely TG, Drobni ZD, Sayour NV, Ferdinandy P, Varga ZV. Molecular fingerprints of cardiovascular toxicities of immune checkpoint inhibitors. Basic Res Cardiol. 2025, 120:187-205. 10.1007\/s00395-024-01068-8","journal-title":"Basic Res Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.06.008","article-title":"Cancer-related immune therapies: bidirectional implications from cardiotoxicity to emerging cardiovascular therapeutics: JACC CardioOncology state-of-the-art review","volume":"7","author":"Miteva K","year":"2025","unstructured":"Miteva K, Anker MS, Fechner H, Lehmann L, Van Linthout S. Cancer-related immune therapies: bidirectional implications from cardiotoxicity to emerging cardiovascular therapeutics: JACC CardioOncology state-of-the-art review. JACC CardioOncol. 2025, 7:523-37. 10.1016\/j.jaccao.2025.06.008","journal-title":"JACC CardioOncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1544532","article-title":"Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond","volume":"16","author":"Yang Z","year":"2025","unstructured":"Yang Z, Ha B, Wu Q, Ren F, Yin Z, Zhang H. Expanding the horizon of CAR T cell therapy: from cancer treatment to autoimmune diseases and beyond. Front Immunol. 2025, 16:1544532. 10.3389\/fimmu.2025.1544532","journal-title":"Front Immunol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.09.009","article-title":"Immune-mediated colitis after immune checkpoint inhibitor therapy","volume":"31","author":"Giesler S","year":"2025","unstructured":"Giesler S, Riemer R, Lowinus T, Zeiser R. Immune-mediated colitis after immune checkpoint inhibitor therapy. Trends Mol Med. 2025, 31:265-80. 10.1016\/j.molmed.2024.09.009","journal-title":"Trends Mol Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2025.49","article-title":"The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy","volume":"8","author":"Zhou M","year":"2025","unstructured":"Zhou M, Huang Z, Ma Z, et al.. The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy. Cancer Drug Resist. 2025, 8:34. 10.20517\/cdr.2025.49","journal-title":"Cancer Drug Resist"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2451296","article-title":"Engineered ipilimumab variants that bind human and mouse CTLA-4","volume":"17","author":"Robison B","year":"2025","unstructured":"Robison B, Diong SJ, Kumar A, et al.. Engineered ipilimumab variants that bind human and mouse CTLA-4. MAbs. 2025, 17:2451296. 10.1080\/19420862.2025.2451296","journal-title":"MAbs"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14176328","article-title":"Cytokine landscapes, immune dysregulation, and treatment perspectives in Philadelphia-negative myeloproliferative neoplasms: a narrative review","volume":"14","author":"Todor SB","year":"2025","unstructured":"Todor SB, Mihaila RG. Cytokine landscapes, immune dysregulation, and treatment perspectives in Philadelphia-negative myeloproliferative neoplasms: a narrative review. J Clin Med. 2025, 14:6328. 10.3390\/jcm14176328","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1042\/EBC20253016","article-title":"Immune-regulating extracellular vesicles: a new frontier in autoimmune disease therapy","volume":"69","author":"Shah H","year":"2025","unstructured":"Shah H, Liu Z, Guo W, Ren W, Xiao Y. Immune-regulating extracellular vesicles: a new frontier in autoimmune disease therapy. Essays Biochem. 2025, 69:161-8. 10.1042\/EBC20253016","journal-title":"Essays Biochem"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06843-2","article-title":"The cGAS-STING pathway: a dual regulator of immune response in cancer and therapeutic implications","volume":"23","author":"Huang Z","year":"2025","unstructured":"Huang Z, Zhu J, Zhou YL, Shi J. The cGAS-STING pathway: a dual regulator of immune response in cancer and therapeutic implications. J Transl Med. 2025, 23:766. 10.1186\/s12967-025-06843-2","journal-title":"J Transl Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01210-5","article-title":"Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3","volume":"23","author":"Grebinoski S","year":"2022","unstructured":"Grebinoski S, Zhang Q, Cillo AR, et al.. Autoreactive CD8(+) T cells are restrained by an exhaustion-like program that is maintained by LAG3. Nat Immunol. 2022, 23:868-77. 10.1038\/s41590-022-01210-5","journal-title":"Nat Immunol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02371-z","article-title":"Immunosenescence: signaling pathways, diseases and therapeutic targets","volume":"10","author":"Fu Y","year":"2025","unstructured":"Fu Y, Wang B, Alu A, et al.. Immunosenescence: signaling pathways, diseases and therapeutic targets. Signal Transduct Target Ther. 2025, 10:250. 10.1038\/s41392-025-02371-z","journal-title":"Signal Transduct Target Ther"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26041453","article-title":"LCAT in cancer biology: embracing epigenetic regulation, immune interactions, and therapeutic implications","volume":"26","author":"Gao M","year":"2025","unstructured":"Gao M, Zhang W, Li X, Li S, Wang W, Han P. LCAT in cancer biology: embracing epigenetic regulation, immune interactions, and therapeutic implications. Int J Mol Sci. 2025, 26:1453. 10.3390\/ijms26041453","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11787","article-title":"Prevalence of autoimmune diseases in patients treated with immune checkpoint inhibitors: an epidemiological study using a global network of health care organizations","volume":"7","author":"Khandwala P","year":"2025","unstructured":"Khandwala P, Desai D, Lau A. Prevalence of autoimmune diseases in patients treated with immune checkpoint inhibitors: an epidemiological study using a global network of health care organizations. ACR Open Rheumatol. 2025, 7:e11787. 10.1002\/acr2.11787","journal-title":"ACR Open Rheumatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi T","year":"2000","unstructured":"Takahashi T, Tagami T, Yamazaki S, et al.. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2000, 192:303-10. 10.1084\/jem.192.2.303","journal-title":"J Exp Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/art.40037","article-title":"A randomized, double-blind trial of abatacept (CTLA-4iG) for the treatment of Takayasu arteritis","volume":"69","author":"Langford CA","year":"2017","unstructured":"Langford CA, Cuthbertson D, Ytterberg SR, et al.. A randomized, double-blind trial of abatacept (CTLA-4iG) for the treatment of Takayasu arteritis. Arthritis Rheumatol. 2017, 69:846-53. 10.1002\/art.40037","journal-title":"Arthritis Rheumatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin X","year":"2024","unstructured":"Lin X, Kang K, Chen P, et al.. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024, 23:108. 10.1186\/s12943-024-02023-w","journal-title":"Mol Cancer"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209856","article-title":"A phase 2 trial of peresolimab for adults with rheumatoid arthritis","volume":"388","author":"Tuttle J","year":"2023","unstructured":"Tuttle J, Drescher E, Sim\u00f3n-Campos JA, et al.. A phase 2 trial of peresolimab for adults with rheumatoid arthritis. N Engl J Med. 2023, 388:1853-62. 10.1056\/NEJMoa2209856","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205218","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review","volume":"13","author":"Shalata W","year":"2021","unstructured":"Shalata W, Abu-Salman A, Steckbeck R, Mathew Jacob B, Massalha I, Yakobson A. Cardiac toxicity associated with immune checkpoint inhibitors: a systematic review. Cancers (Basel). 2021, 13:5218. 10.3390\/cancers13205218","journal-title":"Cancers (Basel)"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.005","article-title":"LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice","volume":"4","author":"Mulholland M","year":"2022","unstructured":"Mulholland M, Kritikou E, Katra P, et al.. LAG3 regulates T cell activation and plaque infiltration in atherosclerotic mice. JACC CardioOncol. 2022, 4:635-45. 10.1016\/j.jaccao.2022.09.005","journal-title":"JACC CardioOncol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.06.002","article-title":"Th17: an effector CD4 T cell lineage with regulatory T cell ties","volume":"24","author":"Weaver CT","year":"2006","unstructured":"Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006, 24:677-88. 10.1016\/j.immuni.2006.06.002","journal-title":"Immunity"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01909","article-title":"Not all immune checkpoints are created equal","volume":"9","author":"De Sousa Linhares A","year":"2018","unstructured":"De Sousa Linhares A, Leitner J, Grabmeier-Pfistershammer K, Steinberger P. Not all immune checkpoints are created equal. Front Immunol. 2018, 9:1909. 10.3389\/fimmu.2018.01909","journal-title":"Front Immunol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.671","article-title":"Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He J","year":"2024","unstructured":"He J, Zeng X, Wang C, Wang E, Li Y. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm (2020). 2024, 5:e671. 10.1002\/mco2.671","journal-title":"MedComm (2020)"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1589853","article-title":"Lactate and lactylation: emerging roles in autoimmune diseases and metabolic reprogramming","volume":"16","author":"Liu W","year":"2025","unstructured":"Liu W, Yang R, Zhan Y, et al.. Lactate and lactylation: emerging roles in autoimmune diseases and metabolic reprogramming. Front Immunol. 2025, 16:1589853. 10.3389\/fimmu.2025.1589853","journal-title":"Front Immunol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-drug conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang R","year":"2025","unstructured":"Wang R, Hu B, Pan Z, et al.. Antibody-drug conjugates (ADCs): current and future biopharmaceuticals. J Hematol Oncol. 2025, 18:51. 10.1186\/s13045-025-01704-3","journal-title":"J Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/428190-immune-checkpoint-dysregulation-in-autoimmune-disorders-a-narrative-review-of-therapeutic-implications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T04:30:54Z","timestamp":1763353854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/428190-immune-checkpoint-dysregulation-in-autoimmune-disorders-a-narrative-review-of-therapeutic-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.97002","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,16]]}}}